Hypertrophic cardiomyopathy (Hypertrophic CardioMyopathy=HCM) remains a poorly understood disease with an assumption insufficiently codified. There is no data available in France on the profile of patients, diagnostic methods and assessment and therapeutic use.

The purpose of this study is to establish a monitoring of patients with HCM (sarcomere of origin or not) in France (diagnosis, treatment)

This both retrospective and prospective study is proposed to cardiology services 50 hospitals in France. A cardiologist referral is designated for each facility.

The following data will be collected by the physician during the initial hospitalization

• Demographics
• Geographic origin of patient
• Clinical data: criteria for inclusion and non-inclusion data HCM general, Doppler ultrasound, personal history, family history
• Reviews made: non-organic, biological
• Family Survey,
• Treatments: Medical, Electrical, invasive
• Data from hospital

The follow-up to 18 months, 3 years and 5 years will be conducted by clinical-research-technicians of the French Society of Cardiology, an application will be made to municipalities of birth and mail a letter to physicians and patients.

The following data will be collected:

• Vital status
• Data from hospital
• Reviews made: non-organic, biological
• Treatments: Medical, Electrical, invasive

Inclusion Criteria:

• Age ≥ 15 years old
• Patient with HCM defined by an ultrasound thickness of the left ventricle ≥ 13 mm if familial or ≥ 15 mm if sporadic

Exclusion Criteria:

• Expressed refusal to participate in the study
• Significant aortic stenosis (<1 cm ²)

Patients ≥ 15 years old with HCM (sarcomere of origin or not) defined by an ultrasound thickness of the left ventricle ≥ 13 mm if familial or ≥ 15 mm if sporadic